The FDA has changed its stance and decided to review Moderna's application to register a new mRNA flu vaccine, although it rejected it in early February. The reason for the original rejection was a dispute over the design of the clinical trial, where the control group, according to the FDA, did not reflect the best available standard of care in the US. Moderna disagreed with the decision, saying it contradicted previous communications from the FDA. After discussions with the FDA and submission of revised proposals, the company announced that the application would be reviewed. The vaccine is intended mainly for adults over 50 years of age and the goal is to have it available in the 2026-2027 flu season. Moderna CEO Stéphane Bancel said they appreciate the constructive engagement with the FDA and look forward to providing new protections to seniors. The vaccine has since been accepted for review in the EU, Canada and Australia.[1][2][3][5]